Asst. Prof. MD. Meltem Topalgökçeli Selam
Medical Oncology
Areas Of Interests
With Advanced Technology and a Patient-Centric Approach, Dr. Meltem Topalgökçeli Selam is a Global Leader in Medical Oncology
Dr. Meltem Topalgökçeli Selam is a distinguished leader in medical oncology, renowned for delivering world-class care that harmonizes profound clinical expertise with a steadfastly patient centric philosophy. Her practice is dedicated to crafting individualized treatment strategies that prioritize patient safety, comfort, and superior clinical outcomes. For individuals facing complex cancer diagnoses such as breast cancer, lung cancer, or gastrointestinal malignancies, Dr. Topalgökçeli Selam employs advanced technology and the latest diagnostic tools to ensure unparalleled precision throughout every phase of care. Her commitment to innovation is highlighted by her skilled application of targeted therapies and immunotherapy, which are instrumental in minimizing side effects and accelerating recovery for her patients.
At the heart of Dr. Topalgökçeli Selam’s approach is a deep commitment to providing compassionate, personalized care. She has cultivated an exceptional reputation for successfully managing a broad spectrum of oncological conditions, tailoring each treatment plan to the unique needs of her patients. By seamlessly integrating the latest advancements in medical oncology, she ensures that every patient benefits from modern, effective, and highly sophisticated treatment solutions. Dr. Topalgökçeli Selam’s practice is fundamentally centered on achieving exceptional results, empowering patients to reclaim their health and quality of life through advanced treatments delivered with genuine empathy and world-class skill.
As a distinguished academic authority in medical oncology, Dr. Meltem Topalgökçeli Selam’s career is marked by a deep commitment to scientific advancement and evidence-based medicine. Her significant influence in the field is demonstrated by her active membership in prestigious organizations such as the Turkish Medical Oncology Association and the Istanbul Breast Research Group. These affiliations underscore her position as a key voice in the global oncology community.
Dr. Topalgökçeli Selam’s practice is built upon a foundation of rigorous scientific research and a dedication to advancing the field through education. Her approach to complex oncological conditions is informed by the latest scientific publications and advanced diagnostics, ensuring that every treatment plan is rooted in proven, current data. With years of experience at leading institutions such as Liv Hospital and Istanbul Faculty of Medicine Oncology Institute, she has played a pivotal role in mentoring future oncologists and advancing cancer care. This dedication to evidence-based practice and academic leadership ensures her patients receive care that is not only state-of-the-art but also backed by world-class scientific expertise, solidifying her reputation as a pivotal figure in modern medical oncology.
1-Ovarian carcinosarcomas:Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.Cicin I,Saip P,Eralp Y,Selam M,Topuz S,Ozluk Y,Aydın Y, Topuz E.Gynecol Oncol. 2007 Oct 11
2-Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.Tas F, Duranyildiz D, Soydinc HO, Cicin I, Selam M, Uygun K, Disci R, Yasasever V,Topuz E.Cancer Chemother Pharmacol. 2007 Jun /
3-Psoriasis agrevatation due to Lapatinib.Selam M.BMJ Case Reports(23 february 2013)
1-Etyolojisi Bilinmeyen Son Dönem Böbrek Yetmezliği Olan Hastalarda Analjezik Nefropatisi Sıklığı ve Tanı Kriterleri.Selam M,Polat H, Kalkan I, Mantar F, Karakullukcu F.
İstanbul Tıp Dergisi 1998 Aralık Cilt 2 Sayı 4 1-5.
2-Sürekli Ambulatuar Periton Diyalizi Hastalarında Oral ve Intraperitoneal 1,25-Dihidroksikolekalsiferol Tedavisi.Kalkan I, Sealm M, Polat H, Caneroğlu U.N, Demirel N, Karakullukcu F.İstanbul Tıp Dergisi 1998 Aralık Cilt 2 Sayı 4 10-14.
3-Bir Olgu Nedeniyle Paget Hastalığı. Benzer M, Selam M, Sametoğlu F.İstanbul Tıp Dergisi 1998 Aralık Cilt 2 Sayı 4 47-50.
4-Tedaviye Yeterli Yanıt Vermeyen Kr. Hepatit B ve Kr. Hepatit C Hastalarında Ursodeoksikolik Asidin Yeri.Demirel N,Caneroğlu U.N,Polat H, Mantar F, Keskin N,Selam M.İstanbul Tıp Dergisi 1998 Ağustos Cilt 2 Sayı 3 8-18.
5-Bir Olgu Nedeniyle Sklederma Adultorum. Ece F,Sezgin Ö, Selam M, Orak E.İsatnbul Tıp Dergisi 1999 Cilt 3 Sayı 4 49-52.
6-Tip II Diabetes Mellitus ve Esansiyel Hipertansif Hastalarda Losartan Potasyum’un Mikroalbuminüri Üzerine Etkisi. Körceğiz A,Polat H,Selam M,Keskin N.İstanbul Tıp Dergisi 1999 Cilt 3 Sayı 1 5-9.
7-Karaciğer Sirozu Etyopatogenezi.Uğurlukişi B,Yoğun Y,Selam M,Özgün E,Kayaş D,Acar A,Kaya B,Karabulut L.Okmeydanı Tıp Dergisi 2004 Cilt 21 Sayı 1 5-9.
8-Tiflit :Çekum İltihabı.Selam M, Yoğun Y,Karabulut L.Okmeydanı Tıp Dergisi 2004 Sayı 3.
9-Poliglandüler Otoimmun Sendromlar (Olgu Sunumu) Yoğun Y,Uğurlukişi B, Selam M,Karabulut L. Okmeydanı Tıp Dergisi 2004 Sayı 3.
- Turkish Medical Oncology Association
- İstanbul Medical Association
- İstanbul Breast Cancer Research Group
- Turkish Lung Cancer Association
- Üsküdar American Academy Graduates Association
